Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment

Department of Psychiatry, University of Rochester, Rochester, New York, United States
Neurology (Impact Factor: 8.3). 08/2006; 67(1):57-63. DOI: 10.1212/01.wnl.0000223333.42368.f1
Source: PubMed

ABSTRACT To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD).
The authors conducted a hypothesis-generating, exploratory analysis of a 24-week, double-blind, placebo-controlled trial comparing memantine (20 mg/day) with placebo in subjects with moderate to severe AD on stable donepezil treatment. They employed the Neuropsychiatric Inventory (NPI; 12-item), administered at baseline, week 12, and week 24, to assess the effects of memantine on behavior. Global, cognitive, and functional measures were collected and relationships between these assessments and changes in behavior were determined. The intent-to-treat population was examined using last-observation-carried-forward and observed-cases approaches.
Patients treated with memantine had significantly lower NPI total scores than patients treated with placebo. Analyses of the 12 NPI domains revealed significant effects in favor of memantine on agitation/aggression, eating/appetite, and irritability/lability. Of patients who exhibited agitation/aggression at baseline, those treated with memantine showed significant reduction of symptoms compared with placebo-treated patients. Memantine-treated patients without agitation/aggression at baseline evidenced significantly less emergence of this symptom compared with similar patients receiving placebo. Caregivers of patients receiving memantine registered significantly less agitation-related distress. There were significant relationships between the NPI and the global rating scale and performance of activities of daily living, but not between changes in the NPI and cognition.
Treatment with memantine reduced agitation/aggression, irritability, and appetite/eating disturbances. Memantine reduced agitation/aggression in patients who were agitated at baseline and delayed its emergence in those who were free of agitation at baseline.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Increasingly, Alzheimer's Disease (AD) is being viewed as a public health threat with prevalence is expected to double in the next 20 years (Alzheimer's Association, 2007). In an effort to improve Alzheimer's care, California's Department of Public Health convened the California Workgroup on Guidelines for Alzheimer's Disease Management, consisting of physicians, researchers, psychologists, nurses and care managers. The original guideline was produced in 1998 and updated in 2002. Its emphasis on integrating primary care with community supports stimulated the development of numerous implementation projects.. It was also unique in its emphasis on culturally sensitive management of AD. The California Workgroup is targeting April as a release date for the 2008 version of the Guideline. Since its last iteration in 2002, there have been a number of evidence-based changes in the management of Alzheimer's disease. The revised guideline will cover these including: The development of a new class of medications for the treatment of Alzheimer's disease, the NMDA receptor agonist. The emergence of a class of early stage patients and evidence about management strategies beneficial to them. A growing body of evidence on the impact of psychotropic medications for behavioral symptoms. A better understanding of the management of end of life care for people with Alzheimer's disease. The proposed presentation will cover the process for the development of the Guideline; review its content, emphasizing areas that have seen evidence-based change in practice; and, give an overview of planned dissemination and implementation strategies developed by the California Workgroup.
    136st APHA Annual Meeting and Exposition 2008; 10/2008
  • [Show abstract] [Hide abstract]
    ABSTRACT: Approximately 5 million Americans have dementia, and many receive psychiatric medications. Management of such patients is complex and controversial, and it has become apparent that all potential pharmacological therapies present risks.
    P&T 04/2015; 40(4):284-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Anomia is often one of the earliest signs of Alzheimer disease (AD), and progressive language impairment remains a major source of disability throughout the disease course.Aims: This article reviews the potential uses of pharmacological adjuvants to augment neuroplasticity during speech and language therapy.Main Contribution: We begin with a discussion of the nature of anomia in AD from the perspective of classical aphasia models and in terms of a parallel distributed processing model of language. Physiological functions of acetylcholine, norepinephrine and dopamine are reviewed. We consider how pharmacological manipulation of these neurotransmitters in combination with speech and language therapy has the potential to promote maintenance and restoration of the functional connectivity within the lexical, semantic and phonological networks that are the basis of propositional language.Conclusions: AD is a disease of synaptic loss. People with AD are able to reacquire knowledge, and pharmacological modulation of acetylcholine, norepinephrine and dopamine can influence the maintenance and reformation of neuronal networks.
    Aphasiology 12/2013; 28(2):219-235. DOI:10.1080/02687038.2013.793283


Available from